Compare Firy Inc. (FIRY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Firy Inc. trades at $8.6 (market cap $125.48M), while Recursion Pharmaceuticals Inc trades at $3.21 (market cap $1.75B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 13.9× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | RXRX | |
|---|---|---|
Market Cap | $125.48M | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $6.79 |
52-Week Low | $2.28 | $2.84 |
Enterprise Value | $69.16M | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $8.04, down 4.74% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. The company recently rebranded and reported Q1 2026 results showing revenue growth to $104.5M but persistent losses with a net margin of -57.48%. Cash flow remains negative at -$86.41M for 2025, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term support at $8, fundamental challenges include deep losses and negative cash flow. Analyst sentiment is mixed with 60% hold ratings. Key risks are profitability timeline and competitive pressure, but rebranding and legal victories may support long-term turnaround if execution improves.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
